Micro,
You have been mostly negative regarding Onxx, which is fine, but you have been most negative at the wrong times. I am posting from my iPhone so don't have my usual access to financial data the whole point of the thread was your post that onxx isn't profitable with one drug and won't be very profitable with Carfizomib, which is absurd.
If you want to talk about profitability or lack there of, then breakdown expense and revenues. It is disingenuous of you to eliminate profits from the sale of Carfilzomib rights to Japan while including all the expenses accrued for the development of Carfilzomib. Try being honest and analytical sometimes. Based on your posting record on the onxx board, you seem to be bitter about when you sold it. Others mentioned it, but I never did until now. My point about Carfilzomib potential rights deals, or should I say likely sales of rights is that it is part of the intrinsic value of Onxx. So are future indications of Nexavar. You seem to want to eliminate future revenues from additional rights sales.
